Jacqueline Shea : I mean that’s a really interesting question. And I would say we remain focused on advancing our DNA medicine candidates that have the greatest scientific promise, clear regulatory path and strongest commercial potential. And that’s really underpinned by our desire to bring to market innovative life-saving DNA medicines for the benefit of patients globally as quickly as possible. With our platform, we’re able to do many different things. I mean we have candidates across infectious disease, HPV-related disease, immuno-oncology. We also have programs in early clinical development in terms of DNA-delivered monoclonal antibodies and then some further earlier preclinical work. But I think what we’re really seeing now with our DNA medicines is our ability to potentially treat HPV-related diseases.
I think it’s going to be very interesting to see how that may translate to other chronic viral diseases. And I think we’re also very excited to see what we can do in the immuno-oncology space, both in HPV-related cancers, but also in some other cancers more broadly. So I think the past few years, we’ve had a lot of data readouts, a lot of encouraging data. And we’re really digging down and analyzing that data to see what it tells us and to really narrow down and focus on where do we really think the best opportunities are for DNA medicines to get potentially life-saving products to patients more quickly. So I hope that…
Operator: The next question is from Gregory Renza with RBC Capital Markets.
Unidentified Analyst: It’s Anish on for Greg. Just a quick one for me here. How should we think about the prioritization of your pipeline programs and the relative investment in each?
Jacqueline Shea : So first of all, as I mentioned in my previous response, we’re really focused on advancing our DNA medicine candidates where we think we have the greatest scientific promise, the strongest commercial potential and a clear regulatory pathway going forward as well. So that’s really what we’re looking at as we assess and evaluate these different opportunities. We’ve had quite a lot of data over the recent months. We’re in the process at the moment, as I said, was really sitting down, going through that data and really prioritizing how we’re going to move our candidates, boards and in what order. And we’ll be providing some further updates on that over the coming months.
Unidentified Analyst: Great. And just to follow up, just the second part of my question there. Is there sort of a difference in the relative investment of time and capital into each of your programs, just given the prudent approach you’ve been taking to resource allocation?
Jacqueline Shea : Yes. So when we’re looking across our pipeline, obviously, we’re considering what the regulatory paths are, what the next steps are, likely costs, time lines, et cetera. And we’re really allocating our resources across the different programs, dependent on that. So I think as Mike mentioned, we’re going to be sitting down and figuring out the path forward for RRP. We’re currently in discussions with the regulators as to the next steps there. And then we’ll may be banking announcements about that program over the coming months. For VGX-3100 as well as he mentioned, this is very recent data. We really need to dig down into the figure out what we can learn from this and how we might want to proceed going forward. We also have other indications for this product candidate as well that we need to take into consideration.
Operator: The next question is from Geoff Meacham with Bank of America.
